Evidence map›Paper›PMID 31845904›Full record

Trial reportThe Journal of clinical investigation2020

Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.

Carolyn M Boudreau, Wen-Han Yu, Todd J Suscovich, H Keipp Talbot, Kathryn M Edwards, Galit Alter

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Plasma Proteomic Profile of Chemotherapy-Induced Severe Neutropenia: A Pilot Discovery Phase Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Carolyn M BoudreauRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Wen-Han YuRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Todd J SuscovichRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
H Keipp TalbotDepartment of Medicine.
Kathryn M EdwardsDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Ragon Institute of MGH, MIT and Harvard · USGovernment of Western Australia Department of Health · AUHarvard University · USVanderbilt University Medical Center · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Demystifying the antiviral activity of the IgG3+ antibody responseR01AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2009 to 2024
$4.1M
Optimization of Broadly Neutralizing Antibodies for HIV EradicationR01AI129797 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2017 to 2021
$3.6M
Tuning Fc-effector functions of HIV-specific antibodiesR01AI102660 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2012 to 2015
$3.0M
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI080289NIAID NIH HHS R01 AI102660NIAID NIH HHS R01 AI129797NIAID NIH HHS R37 AI080289NIAID NIH HHS T32 AI007245
6 · The paper itself

Abstract

Seasonal and pandemic influenza infection remains a major public health concern worldwide. Driving robust humoral immunity has been a challenge given preexisting, often cross-reactive, immunity and in particular, poorly immunogenic avian antigens. To overcome immune barriers, the adjuvant MF59 has been used in seasonal influenza vaccines to increase antibody titers and improve neutralizing activity, translating to a moderate increase in protection in vulnerable populations. However, its effects on stimulating antibody effector functions, including NK cell activation, monocyte phagocytosis, and complement activity, all of which have been implicated in protection against influenza, have yet to be defined. Using systems serology, we assessed changes in antibody functional profiles in individuals who received H5N1 avian influenza vaccine administered with MF59, with alum, or delivered unadjuvanted. MF59 elicited antibody responses that stimulated robust neutrophil phagocytosis and complement activity. Conversely, vaccination with MF59 recruited NK cells poorly and drove moderate monocyte phagocytic activity, both likely compromised because of the induction of antibodies that did not bind FCGR3A. Collectively, defining the humoral antibody functions induced by distinct adjuvants may provide a path to designing next-generation vaccines that can selectively leverage the humoral immune functions, beyond binding and neutralization, resulting in better protection from infection.

Indexed as

Influenza VaccinesPolysorbatesSqualeneVaccinationAdolescentAdultAntibodies, ViralComplement System ProteinsFemaleHumansInfluenza A Virus, H5N1 SubtypeKiller Cells, NaturalMaleMiddle AgedMonocytesNeutrophilsAntibodies, ViralComplement System ProteinsInfluenza VaccinesMF59 oil emulsionPolysorbatesSqualeneAdaptive immunityImmunologyInfluenzaInnate immunityVaccines

Identifiers

PMID31845904
PMCPMC6994146
OpenAlexW2996239873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.